Rising prevalence rate of psychosis and associated diseases is primarily fuelling the antipsychotic drugs market size over the forecast time frame. Additional factors contributing in industry growth rate are substance-induced psychoses, genetic mutations, and physical illness resulting in depression.
The global antipsychotic drugs market is expected to be around US$ 16 billion by 2028 at a compound annual growth rate (CAGR) of 2%.
Launch of innovative antipsychotic compounds accompanied with high R&D investments will further boost the antipsychotic drugs industry share till 2025. Moreover, rising efforts by the industry players to expand therapeutic applications of such medicines are estimated to create opportunities for enhancing antipsychotics portfolio over the coming years.
Global antipsychotic drugs market is segmented based on the drug as, first generation, second generation, and third generation. On the basis of application, the global antipsychotic drugs market is segregated as Schizophrenia, Dementia, Bipolar Disorder, Unipolar Depression, and others. Schizophrenia is expected to witness notable gains in the forecast years.
Global antipsychotic drugs market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional antipsychotic drugs market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global antipsychotic drugs market share consists of several players including Pfizer; AstraZeneca, Johnson & Johnson; Allergan, Eli Lilly; Glaxo SmithKline, and Bristol-Myers Squibb.
The Antipsychotic Drugs Market has been segmented as below:
Antipsychotic Drugs Market, By Product
Antipsychotic Drugs Market, By Application
Antipsychotic Drugs Market, By Region
The report covers:
Report scope:
The global antipsychotic drugs market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer; AstraZeneca, Johnson & Johnson; Allergan, Eli Lilly; Glaxo SmithKline, and Bristol-Myers Squibb.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
Nonalcoholic Steatohepatitis market
Robotic Pharmacy Prescription Dispensing Systems Market
Sexually Transmitted Disease Therapeutics Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising prevalence of psychosis and associated disorders
4.2.2. Continuous investment in R&D
4.3. Restraints
4.3.1. Rising social awareness regarding psychotic disorders
4.3.2. Patent expiry of major drugs
4.4. Opportunities
4.4.1. Access and availability of medicines for treatment
4.4.2. Introduction of generic versions
4.5. Challenges
4.5.1. Adverse effects and chance of habit formation
5. Antipsychotic Drugs Market, By Drug
5.1. Key Points
5.2. First Generation
5.2.1. Haldo
5.2.2. Navane
5.2.3. Others
5.3. Second Generation
5.3.1. Invega
5.3.2. Latuda
5.3.3. Seroquel
5.3.4. Risperdal
5.3.5. Zyprexa
5.3.6. Geodon
5.3.7. Others
5.4. Third generation
5.4.1. Abilify
6. Antipsychotic Drugs Market, By Application
6.1. Key Points
6.2. Schizophrenia
6.3. Bipolar disorders
6.4. Dementia
6.5. Unipolar Depression
6.6. Others
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Pfizer
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. AstraZeneca
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. Johnson & Johnson
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Allergan
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Eli Lilly
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. GlaxoSmithKline
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. Bristol-Myers Squibb
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
The Antipsychotic Drugs Market has been segmented as below:
Antipsychotic Drugs Market, By Product
Antipsychotic Drugs Market, By Application
Antipsychotic Drugs Market, By Region
